Back

Use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation across five stages of chronic kidney diseases

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations Oral Anticoagulation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Tze-Fan Chao

Taipei Veterans General Hospital, Taipei (Taiwan)

4 More presentations in this session

Presentation thumbnail
Predictors and outcomes of intracranial hemorrhage in 58,000 patients with atrial fibrillation on oral anticoagulation: insights from COMBINE-AF
Doctor M. Tannu (Durham, US)
Abstract Slides Video
Presentation thumbnail
Anticoagulation and stroke in hospitalized patients newly diagnosed with secondary atrial fibrillation: a population-based cohort study
Doctor H. Abdel-Qadir (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Post-operative atrial fibrillation during cardiac rehabilitation: incidence and long-term prognostic value.
Doctor S. Rastelli (IT)
Abstract Slides Video
Presentation thumbnail
Risk of thromboembolic and haemorrhagic events associated with anticoagulation among 11,355 patients with non-valvular atrial fibrillation and thrombocytopenia
Doctor M. Tam (Shatin, HK)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Presentation
Oral anticoagulation in subclinical atrial fibrillation: pro

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources